Mirvetuximab ELISA Kit

Catalog No.

KDD10402

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human FOLR1 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Mirvetuximab in the sample competitively binds to the pre-coated protein with biotin-labeled Mirvetuximab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Mirvetuximab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Mirvetuximab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

46.88 - 3,000 ng/mL

Sensitivity

35.26 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1100.3	252.5	211.7	1200.6	322.5	212.4
Standard deviation	124.2	31.0	28.3	207.5	40.9	30.2
CV (%)	11.3	12.3	13.4	17.3	12.7	14.2

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

M9346A, IMGN853, M9346A-sulfo-SPDB-DM4, CAS: 1453084-36-0

Background

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells.

Note

For Research Use Only.

Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis., PMID:38788019

Ocular toxicities associated with antibody drug conjugates., PMID:38814581

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial., PMID:38858103

Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases., PMID:38914019

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities., PMID:38941962

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer., PMID:39061184

Mirvetuximab after anaphylaxis to Paclitaxel: A case report., PMID:39076678

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer., PMID:39082675

Accuracy and Completeness of Large Language Models About Antibody-Drug Conjugates and Associated Ocular Adverse Effects., PMID:39110155

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]., PMID:39191683

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)., PMID:39228525

Near fatal case of mirvetuximab soravtansine-gynx induced interstitial lung disease and a review of the primary literature., PMID:39281842

Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen., PMID:39307840

Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer., PMID:39378056

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary., PMID:39461270

The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis., PMID:39526448

Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers., PMID:39590153

Folate Receptor Alpha-A Secret Weapon in Ovarian Cancer Treatment?, PMID:39595996

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial., PMID:39617145

Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers., PMID:39631181

Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy., PMID:39640287

Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680

Mirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis., PMID:39729462

Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine., PMID:39734248

Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines., PMID:39900344

A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective., PMID:39922351

Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies., PMID:39970828

Mirvetuximab soravtansine shines post-PARP inhibitor progression: promising insights from the PICCOLO trial., PMID:39988550

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells., PMID:39996761

[Mirvetuximab soravtansine as monotherapy in platinum-resistant ovarian cancer expressing alpha folate receptor]., PMID:40016053

Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer., PMID:40028469

IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer., PMID:40029935

Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial., PMID:40044930

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report., PMID:40050918

Mirvetuximab soravtansine: current and future applications., PMID:40102896

Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine., PMID:40109581

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate., PMID:40121972

A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer., PMID:40126684

Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics., PMID:40139025

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial., PMID:40179908

Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer., PMID:40242965

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer., PMID:40270982

Ovarian Cancer Therapy., PMID:40389314

Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758

State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers., PMID:40489723

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters., PMID:40501953

Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker., PMID:40508029

Document Download

Mirvetuximab ELISA Kit.pdf